If 23andMe is sold, merges with another company, or goes through bankruptcy, your genetic and personal data may be transferred to the new owner as part of that transaction.
This analysis describes what 23andMe's agreement states, permits, or reserves. It does not constitute a legal determination about enforceability. Regulatory applicability and practical outcomes may vary by jurisdiction, enforcement context, and individual circumstances. Read our methodology
This provision is particularly significant given that 23andMe has publicly reported financial difficulties; it means your most sensitive personal data, your DNA, could be acquired and controlled by an entity you did not originally consent to share it with.
Interpretive note: The document's summary version references account deletion and data discard but the full business transfer clause language was truncated in the provided document; the provision's exact scope is inferred from standard 23andMe policy language and the document context.
The updated privacy statement no longer explicitly directs users to a separate Medical Record Privacy Notice for telehealth services or explains that medical information collected through telehealth is governed by different privacy rules. Previously, the policy stated that users choosing telehealth services coordinated through 23andMe would find healthcare privacy protections described in a separate notice. That reference is now absent from the main privacy statement. Users seeking privacy information specific to telehealth services will need to determine independently whether a separate notice exists or contact 23andMe directly using the provided contact information.
View change record →The updated privacy statement no longer explicitly discloses a separate Medical Record Privacy Notice that previously described how medical information is used, disclosed, and maintained for telehealth services. Users who receive telehealth services coordinated through 23andMe may now lack clear notice of which privacy framework governs their medical records, since the reference to that parallel notice has been removed. The organizational scope change from '23andMe Research Institute' to '23andMe' narrows the explicitly named entities responsible for the policy, though operational impact depends on how these entities actually function.
View change record →The agreement authorizes transfer of genetic information, self-reported health data, and account data to a successor entity in a merger, acquisition, or bankruptcy proceeding, and users have limited ability to prevent this transfer once it occurs, though deletion prior to such a transaction would remove their data from the transferred assets.
How other platforms handle this
At Ledger, earning and maintaining our users' trust is a top priority. That's why we are deeply committed not only to protecting your privacy and securing your personal data, but also to being fully transparent about how we handle it.
If you are located in the European Economic Area, Switzerland, or the United Kingdom, you have the right to access, correct, or erase your personal data; the right to restrict or object to our processing of your personal data; the right to data portability; and, where our processing is based on your...
We use information to enhance the quality, reliability, and/or accuracy of our AI Features by creating, developing, training, testing, improving, and maintaining AI and ML models run by Strava or our service providers. We use aggregated, de-identified data for this purpose. We also use personal info...
Monitoring
23andMe has changed this document before.
Receive same-day alerts, structured change summaries, and monitoring for up to 25 platforms.
"You can delete your 23andMe account any time. If you do, we will automatically opt you out of Research and discard your sample. Keep in mind this process cannot be cancelled or reversed.— Excerpt from 23andMe's 23andMe Privacy Statement
REGULATORY LANDSCAPE: Business transfer clauses involving genetic data engage GDPR Article 6 lawful basis requirements and Article 9 for special category data, as a change of data controller in an acquisition or bankruptcy typically requires assessment of whether the original consent basis extends to the new controller. The FTC has historically scrutinized data transfers in bankruptcy proceedings where assets include sensitive personal data. California CCPA and the California Genetic Information Privacy Act may also impose obligations on successor entities that acquire California residents' genetic data. GOVERNANCE EXPOSURE: High. Transfer of genomic data to a successor entity without requiring fresh consent from users creates material regulatory exposure under GDPR and may engage FTC scrutiny under the FTC Act's unfair practices authority, particularly if the successor entity's intended use of the data differs from the original consent. The sensitivity of genomic data amplifies this exposure relative to standard business transfer clauses. JURISDICTION FLAGS: EU and UK users are subject to GDPR and UK GDPR, which impose strict controller-change notification and lawful basis requirements. California residents may have rights under CCPA to opt out of sale or transfer. The bankruptcy context may also trigger court supervision of data transfer under US bankruptcy law, and the FTC has intervened in prior consumer data bankruptcies. CONTRACT AND VENDOR IMPLICATIONS: Procurement and M&A teams reviewing any transaction involving 23andMe should treat the genomic data asset as requiring specialized due diligence. The transferability of user consent obtained under the current policy to a successor entity is a material open question that should be addressed in transaction documents and any regulatory notifications. COMPLIANCE CONSIDERATIONS: Legal teams should evaluate whether pre-transaction user notification and opt-out mechanisms are required under applicable law before any business transfer closes. Data mapping should identify the volume and categories of genetic and health data subject to transfer. EU and UK regulatory authorities may require notification of a controller change. A fresh consent mechanism for Research participation post-transfer may be legally necessary under GDPR.
Full compliance analysis
Regulatory citations, enforcement risk, and due diligence action items.
Free: track 1 platform + weekly digest. Monitor: 25 platforms + same-day alerts. No credit card required.
Ad personalization controls removed. Contact scanning added. Advertiser data partnerships quietly dropped. A timeline of every change.
Compliance Governance Intelligence
Need to monitor specific governance provisions?
Compliance includes provision-level monitoring, governance timelines, regulatory mapping, and audit-ready analysis.
Built from archived source documents, structured governance mappings, and historical version tracking.
This provision is particularly significant given that 23andMe has publicly reported financial difficulties; it means your most sensitive personal data, your DNA, could be acquired and controlled by an entity you did not originally consent to share it with.
The agreement authorizes transfer of genetic information, self-reported health data, and account data to a successor entity in a merger, acquisition, or bankruptcy proceeding, and users have limited ability to prevent this transfer once it occurs, though deletion prior to such a transaction would remove their data from the transferred assets.
No. ConductAtlas is an independent monitoring service. We are not affiliated with, endorsed by, or sponsored by 23andMe.